Protara Therapeutics Inc (TARA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protara Therapeutics Inc (TARA) has a cash flow conversion efficiency ratio of -0.087x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.06 Million) by net assets ($161.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TARA market cap overview for the company's overall valuation and market capitalisation.
Protara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Protara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Protara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protara Therapeutics Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Protara Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jasmine International Public Company Limited
BK:JAS
|
0.020x |
|
SMC Global Securities Limited
NSE:SMCGLOBAL
|
-0.162x |
|
Coca Cola HBC AG
LSE:CCH
|
0.137x |
|
EIH Associated Hotels Limited
NSE:EIHAHOTELS
|
0.023x |
|
Unison Co. Ltd
KQ:018000
|
-0.080x |
|
Rxsight Inc
NASDAQ:RXST
|
-0.036x |
|
China Dongxiang (Group) Co. Ltd
F:4C1
|
0.001x |
|
Niko Semiconductor Co Ltd
TWO:3317
|
0.036x |
Annual Cash Flow Conversion Efficiency for Protara Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Protara Therapeutics Inc from 2012 to 2025. View today's stock price for Protara Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.41 Million | $-56.37 Million | -0.287x | -33.94% |
| 2024-12-31 | $167.13 Million | $-35.81 Million | -0.214x | +61.03% |
| 2023-12-31 | $68.32 Million | $-37.56 Million | -0.550x | -112.10% |
| 2022-12-31 | $102.08 Million | $-26.46 Million | -0.259x | -21.63% |
| 2021-12-31 | $161.91 Million | $-34.50 Million | -0.213x | -81.38% |
| 2020-12-31 | $199.24 Million | $-23.41 Million | -0.117x | +95.20% |
| 2019-12-31 | $6.39 Million | $-15.65 Million | -2.448x | -115.38% |
| 2018-12-31 | $20.44 Million | $-23.23 Million | -1.136x | -76.63% |
| 2017-12-31 | $34.74 Million | $-22.35 Million | -0.643x | -4.42% |
| 2016-12-31 | $38.44 Million | $-23.69 Million | -0.616x | -122.42% |
| 2015-12-31 | $63.41 Million | $-17.57 Million | -0.277x | -128.68% |
| 2014-12-31 | $82.46 Million | $-9.99 Million | -0.121x | -107.43% |
| 2013-12-31 | $-4.11 Million | $-6.70 Million | 1.631x | +171.92% |
| 2012-12-31 | $3.63 Million | $-8.23 Million | -2.268x | -- |
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more